口服药物治疗勃起功能障碍:AFU/SFMS系统审查
Ala Chebbi1, Hugo Dupuis2, Diana Kassab3
1Polyclinique de la région Mantaise, Mantes-la-Jolie, France; Department of Urology, Saint-Joseph Hospital, Paris, France.
The French journal of urology
|September 7, 2025
概括
口服固酶-5抑制剂 (PDE5I) 是治疗勃起功能障碍 (ED) 的有效方法. 所有的PDE5抑制剂都表现出类似的疗效和安全性,塔达拉菲尔为个性化的患者护理提供了日常使用的灵活性.
科学领域:
- 药理学 药理学是指药理学的学科.
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 临床医学 临床医学
背景情况:
- 勃起功能障碍 (ED) 是一种常见的疾病,影响着许多男性.
- 口服固酶-5抑制剂 (PDE5I) 是ED的主要治疗方式.
研究的目的:
- 评估ED治疗中口服PDE5抑制剂的疗效和安全性.
- 为了比较不同的PDE5抑制剂,并确定它们对不同患者群体的适用性.
主要方法:
- 从1999-2023年对文献进行系统审查,包括元分析,RCT和前性研究.
- 分析的重点是法国使用的西尔德纳菲尔,塔达拉菲尔,瓦尔德纳菲尔和阿瓦纳菲尔.
- 结果包括IIEF,SEP评分和不良事件概况.
主要成果:
- 所有四种PDE5抑制剂都表现出可比的疗效和毒性.
- 西尔德纳菲尔,瓦尔德纳菲尔和阿瓦纳菲尔具有相似的药理动力学; 塔达拉菲尔允许每日剂量.
- 副作用是轻微的 (头痛,消化不良);塔达拉菲尔的耐受性很高,每日使用和按需使用之间没有显著的疗效差异.
结论:
- PDE5抑制剂是有效的第一线ED治疗,具有相似的特征.
- 治疗选择应与患者的需求,并发症和生活方式保持一致.
- 建议对特定亚群进行进一步的研究,以完善临床指南.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
571
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
571
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
257
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
257
Disorders of the Male Reproductive System
4.0K
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
4.0K
Male Sexual Response: Erection & Ejaculation
19.2K
Sexual stimulation can take various forms, such as physical touch and visual or auditory cues. When this happens, the parasympathetic reflex in the sacral portion of the spinal cord is activated. This reflex stimulates the release of nitric oxide (NO), which then dilates the arterioles in the penis, increasing blood flow to the erectile tissues - the corpora cavernosa and corpus spongiosum.
The blood filling the erectile tissues compresses the veins, which helps to prevent blood from leaving...
The blood filling the erectile tissues compresses the veins, which helps to prevent blood from leaving...
19.2K
Antidepressant Drugs: MAOIs and Other Agents
831
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
831
Heart Failure V: Medical Management
223
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
223


